BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24331344)

  • 1. Deferred permanent prostate seed brachytherapy does not affect PSA outcome: results from a large retrospective cohort.
    Chira C; Delouya G; Gruszczynski N; Donath D; Taussky D
    Can J Urol; 2013 Dec; 20(6):7028-34. PubMed ID: 24331344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of metastatic disease after prostate brachytherapy.
    Forsythe K; Burri R; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):645-52. PubMed ID: 22137025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
    Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy.
    Fang LC; Merrick GS; Butler WM; Galbreath RW; Murray BC; Reed JL; Adamovich E; Wallner KE
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):992-6. PubMed ID: 20932674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy versus external-beam radiotherapy for localized prostate cancer: long-term effect on biochemical control-in search of the optimal treatment.
    González-San Segundo C; Herranz-Amo F; Alvarez-González A; Cuesta-Álvaro P; Gómez-Espi M; Paños-Fagundo E; Santos-Miranda JA
    Ann Surg Oncol; 2011 Oct; 18(10):2980-7. PubMed ID: 21431406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.
    Burri RJ; Ho AY; Forsythe K; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1315-21. PubMed ID: 20044216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
    Zelefsky MJ; Ben-Porat L; Scher HI; Chan HM; Fearn PA; Fuks ZY; Leibel SA; Venkatraman ES
    J Clin Oncol; 2005 Feb; 23(4):826-31. PubMed ID: 15681527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.
    Critz FA; Williams WH; Levinson AK; Benton JB; Schnell FJ; Holladay CT; Shrake PD
    J Urol; 2003 Nov; 170(5):1864-7. PubMed ID: 14532794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.